AR107560A1 - Compuesto que disminuye la glucosa en la sangre - Google Patents
Compuesto que disminuye la glucosa en la sangreInfo
- Publication number
- AR107560A1 AR107560A1 ARP170100312A ARP170100312A AR107560A1 AR 107560 A1 AR107560 A1 AR 107560A1 AR P170100312 A ARP170100312 A AR P170100312A AR P170100312 A ARP170100312 A AR P170100312A AR 107560 A1 AR107560 A1 AR 107560A1
- Authority
- AR
- Argentina
- Prior art keywords
- chain
- cysteine
- compound
- blood
- disulfide bond
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 abstract 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere al campo de la medicina y al tratamiento de la diabetes o hiperglucemia dentro de ese campo. Reivindicación 1: Un compuesto, caracterizado porque comprende una cadena A y una cadena B, en donde la secuencia de aminoácidos de la cadena A es SEC ID Nº 1 y la secuencia de aminoácidos de la cadena B es SEC ID Nº 2, y en donde las cadenas A y B contienen un enlace de disulfuro entre la cisteína en la posición 7 de la cadena A y la cisteína en la posición 7 de la cadena B, un enlace de disulfuro entre la cisteína en la posición 20 de la cadena A y la cisteína en la posición 19 de la cadena B, y un enlace de disulfuro entre la cisteína en la posición 6 de la cadena A y la cisteína en la posición 11 de la cadena A.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662299131P | 2016-02-24 | 2016-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107560A1 true AR107560A1 (es) | 2018-05-09 |
Family
ID=58191654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100312A AR107560A1 (es) | 2016-02-24 | 2017-02-08 | Compuesto que disminuye la glucosa en la sangre |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10035839B2 (es) |
| JP (1) | JP6320648B1 (es) |
| AR (1) | AR107560A1 (es) |
| JO (2) | JOP20170040B1 (es) |
| TW (1) | TWI633116B (es) |
| WO (1) | WO2017146979A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5843357B2 (ja) | 2009-02-03 | 2016-01-13 | アムニクス オペレーティング インコーポレイテッド | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 |
| CN113597434B (zh) | 2019-12-31 | 2022-07-01 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| WO2022068920A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| JP5843357B2 (ja) * | 2009-02-03 | 2016-01-13 | アムニクス オペレーティング インコーポレイテッド | 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物 |
| EA037979B1 (ru) | 2012-02-27 | 2021-06-18 | Амуникс Оперейтинг Инк. | Композиции конъюгата xten и способы их получения |
| AR090843A1 (es) * | 2012-05-09 | 2014-12-10 | Lilly Co Eli | Tratamiento para diabetes comorbida con enfermedad renal cronica |
-
2017
- 2017-02-08 AR ARP170100312A patent/AR107560A1/es unknown
- 2017-02-09 JO JOP/2017/0040A patent/JOP20170040B1/ar active
- 2017-02-09 TW TW106104216A patent/TWI633116B/zh active
- 2017-02-16 JP JP2017552503A patent/JP6320648B1/ja active Active
- 2017-02-16 US US15/434,477 patent/US10035839B2/en active Active
- 2017-02-16 WO PCT/US2017/018085 patent/WO2017146979A1/en not_active Ceased
-
2021
- 2021-07-27 JO JOP/2021/0201A patent/JOP20210201A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10035839B2 (en) | 2018-07-31 |
| JP2018513854A (ja) | 2018-05-31 |
| JP6320648B1 (ja) | 2018-05-09 |
| WO2017146979A1 (en) | 2017-08-31 |
| JOP20210201A1 (ar) | 2023-01-30 |
| TW201738265A (zh) | 2017-11-01 |
| JOP20170040B1 (ar) | 2021-08-17 |
| US20170240614A1 (en) | 2017-08-24 |
| TWI633116B (zh) | 2018-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107560A1 (es) | Compuesto que disminuye la glucosa en la sangre | |
| MX2020008271A (es) | Inhibidor de fap. | |
| PE20191836A1 (es) | Compuesto de insulina acilada | |
| CY1115649T1 (el) | Σκευασματα ινσουλινων μακρας-δρασης | |
| CL2021002397A1 (es) | Derivados de insulina sensibles a la glucosa | |
| CR11179A (es) | Anticuerpos humanizados contra el globometro ab (20-42) y sus usos | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| JOP20190103A1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
| MX377688B (es) | Métodos para administrar óxido nítrico a la sangre arterial o arterializada. | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| MX2015014007A (es) | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada. | |
| EA201891608A1 (ru) | Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| EA201891610A1 (ru) | Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| BR112021026364A2 (pt) | Antígenos de câncer e métodos | |
| PE20210123A1 (es) | Compuesto de anillo de metillactama y uso farmaceutico del mismo | |
| MX2019002248A (es) | Proteina de union al factor h modificada. | |
| MX2018011121A (es) | Prevención de la adherencia de tejido biológico. | |
| CY1119520T1 (el) | Αλατα 1-(3-μεθυλ-2-οξο-2,3-διυδρο-1,3-βενζοξαζολ-6-υλ)-2,4-διοξο-3-[(1r)-4-(τριφθορομεθυλ)-2,3-διυδρο-1η-ινδενο-1-υλ]-1,2,3,4-τετραϋδροπυριμιδιν-5-καρβοξυλικου οξεος | |
| CL2017000578A1 (es) | Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia | |
| AR087811A1 (es) | Vacuna contra el staphylococcus aureus | |
| DOP2016000096A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| CY1120861T1 (el) | Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1 | |
| AR121038A1 (es) | Derivados de insulina sensibles a glucosa | |
| AR107295A1 (es) | Administración intradérmica de una composición de inmunoglobulina g | |
| TWD189840S (zh) | necklace |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |